                         SEQUENCE LISTING

<110>  Eli Lilly and Company
 
<120>  Tirzepatide Therapeutic Methods

<130>  X22988

<150>  US 63/150,187
<151>  2021-02-17

<160>  1     

<170>  PatentIn version 3.5

<210>  1
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa at position 2 is nonnaturally occurring amino acid 
       2-Aminoisobutyric Acid

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa at position 13 is nonnaturally occurring amino acid 
       2-Aminoisobutyric Acid

<220>
<221>  MOD_RES
<222>  (20)..(20)
<223>  Lys at position 20 is chemically modified through conjugation to 
       the epsilon-amino group of the K side-chain with 
       (2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(gamma-Glu)1-CO-(CH2)18-C
       O2H

<220>
<221>  MOD_RES
<222>  (39)..(39)
<223>  Ser at position 39 is amidated as a C-terminal primary amide

<400>  1

Tyr Xaa Glu Gly Thr Phe Thr Ser Asp Tyr Ser Ile Xaa Leu Asp Lys 
1               5                   10                  15      


Ile Ala Gln Lys Ala Phe Val Gln Trp Leu Ile Ala Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Pro Ser 
        35                  


